OPNT - Opiant Pharmaceuticals starts dosing in OPNT003 study

Opiant Pharmaceuticals (OPNT) announces that the first subjects were dosed in a head-to-head clinical study comparing the effectiveness of its investigational opioid antagonist OPNT003, nasal nalmefene, with nasal naloxone.The single-center, randomized, open-label study in heathy volunteers will evaluate the effectiveness of 3mg nasal nalmefene, in comparison to 4 mg nasal naloxone, to reverse the respiratory depression produced by the synthetic opioid, remifentanil.Top-line data from the trial is expected in the fourth quarter of 2021, the company said.The development of OPNT003 is supported by grants from the National Institute on Drug Abuse, part of the National Institutes of Health, and the Biological Advance Research and Development Agency.

For further details see:

Opiant Pharmaceuticals starts dosing in OPNT003 study